Mesa Biotech to Demonstrate New Accula Molecular POC Testing Platform at Medica 2018

Company to Participate in USA Corporate Executive Office Program SAN DIEGO, CA – November 6, 2018 – Mesa Biotech, Inc, a privately-held, molecular diagnostic company that has developed an affordable and easy to operate PCR (polymerase chain reaction) testing platform designed specifically for point-of-care (POC), today announced its participation in the U.S. Commercial Service’s Corporate Executive Office (CEO) at Medica. Medica, the world’s largest medical technology trade show, is being held on November 12 - 15, 2018 in Dusseldorf, Germany. Mesa Biotech will be available to discuss commercialization opportunities for its Accula™ Test System, including the Accula Flu A/Flu B Test, which obtained CE Mark in the EU and 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) earlier in the year.
Created to help U.S. companies export their products and services throughout the world, the U.S. Commercial Service is hosting the CEO Center at Medica 2018. The Center offers a unique opportunity for participating U.S. companies to promote their exports, and meet new customers and qualified distributors from all over Europe and the world at an affordable cost. 
“Participation in the CEO Center at Medica is a valuable opportunity for Mesa Biotech, enabling us to reach the world market and promote our Accula System, including our Accula Flu A/Flu B test,” said Hong Cai, Co-founder and Chief Executive Officer, Mesa Biotech, Inc. “International trade specialists representing over 15 major markets will be available to facilitate one-on-one introductions, as well as access to in-country expertise and market intelligence. We look forward to expanding our distribution network and bringing the significant benefits of the Accula System to clinicians and patients throughout the world.”
About Mesa Biotech Inc.
Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care (POC). Mesa Biotech’s Accula^™ System consists of a portable, palm-sized dock and disposable, assay-specific test cassettes. This patented system enables healthcare professionals to access actionable, laboratory-quality results at the POC with greater sensitivity and specificity than current infectious disease rapid immunoassay tests. The Accula Flu A/Flu B Test, Mesa Biotech’s first product to market, has obtained CE Mark in the EU and 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA). For more information visit http://www.mesabiotech.com.